Insmed Inc Asset Resilience Ratio
Insmed Inc asset resilience ratio. Insmed Inc (INSM) has an Asset Resilience Ratio of 56.98% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read INSM total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Insmed Inc (1999–2024)
Asset resilience ratio of Insmed Inc from 1999 to 2024. This chart shows how Insmed Inc's Asset Resilience Ratio has changed over time. See INSM cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Insmed Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Insmed Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.35 Billion | 56.98% |
| Total Liquid Assets | $1.35 Billion | 56.98% |
Asset Resilience Insights
- Very High Liquidity: Insmed Inc maintains exceptional liquid asset reserves at 56.98% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Insmed Inc Industry Peers by Asset Resilience Ratio
Compare Insmed Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
89bio Inc
NASDAQ:ETNB |
Biotechnology | 71.60% |
|
Eikon Therapeutics, Inc. Common Stock
NASDAQ:EIKN |
Biotechnology | 49.84% |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399 |
Biotechnology | 37.23% |
|
Larimar Therapeutics Inc
NASDAQ:LRMR |
Biotechnology | 38.46% |
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Equillium Inc
NASDAQ:EQ |
Biotechnology | 0.00% |
|
iNtRON Biotechnology Inc
KQ:048530 |
Biotechnology | 10.90% |
Insmed Inc Asset Resilience Ratio by Year (1999–2024)
Insmed Inc asset resilience ratio by year from 1999 to 2024. The table below shows the annual Asset Resilience Ratio data for Insmed Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 43.39% | $878.80 Million | $2.03 Billion | +20.98pp |
| 2023-12-31 | 22.41% | $298.07 Million | $1.33 Billion | +17.93pp |
| 2022-12-31 | 4.48% | $74.24 Million | $1.66 Billion | -- |
| 2021-12-31 | 0.00% | $0.00 | $1.24 Billion | -- |
| 2017-12-31 | 0.00% | $0.00 | $462.05 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $237.96 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $356.56 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $230.86 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $176.50 Million | -- |
| 2012-12-31 | 1.40% | $2.15 Million | $153.56 Million | -42.52pp |
| 2011-12-31 | 43.93% | $61.42 Million | $139.83 Million | -5.65pp |
| 2010-12-31 | 49.58% | $97.31 Million | $196.26 Million | -36.80pp |
| 2009-12-31 | 86.38% | $109.44 Million | $126.69 Million | +81.09pp |
| 2008-12-31 | 5.30% | $252.00K | $4.76 Million | -60.99pp |
| 2007-12-31 | 66.28% | $12.93 Million | $19.50 Million | +64.85pp |
| 2006-12-31 | 1.44% | $407.00K | $28.35 Million | +0.19pp |
| 2005-12-31 | 1.25% | $285.00K | $22.87 Million | -0.94pp |
| 2004-12-31 | 2.19% | $285.00K | $13.01 Million | -8.96pp |
| 2000-12-31 | 11.15% | $11.46 Million | $102.72 Million | -70.39pp |
| 1999-12-31 | 81.55% | $4.32 Million | $5.30 Million | -- |
About Insmed Inc
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antiba… Read more